The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0

作者：

Castro, Daniela ^{[1
]}

Tripathi, Nishita ^{[2
]}

Sayegh, Nicolas ^{[2
]}

Gebrael, Georges ^{[2
]}

Li, Xiaochen ^{[1
]}

Meza, Luis ^{[1
]}

Zengin, Zeynep ^{[1
]}

Chehrazi-Raffle, Alex ^{[1
]}

Govindarajan, Ameish ^{[1
]}

Dizman, Nazli ^{[1
,3
]}

Ebrahimi, Hedyeh ^{[1
]}

Chawla, Neal ^{[1
]}

Mercier, Benjamin ^{[1
]}

Hsu, Joann ^{[1
]}

Shi, Jessica ^{[1
]}

Philip, Errol ^{[4
]}

Bergerot, Cristiane ^{[5
]}

Barragan-Carrillo, Regina ^{[1
,6
]}

Pal, Sumanta ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA

[2] Univ Utah, Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA

[3] Yale Univ, Dept Internal Med, Sch Med, New Haven, CT USA

[4] Univ Calif San Francisco, San Francisco, CA USA

[5] Ctr Canc Brasilia CETTRO, Inst Unity Ensino & Pesquisa, Brasilia, DF, Brazil

[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico

来源：

ONCOLOGIST | 2023年 / 28卷

关键词：

insurance status; clinical outcomes; disparities; social determinants of health;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S5 / +

页数：2

共 50 条

[1] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
Halabi, S.
Rini, B. I.
Stadler, W. M.
Small, E. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[2] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
Verzoni, Elena
Iacovelli, Roberto
Rizzo, Mimma
Felici, Alessandra
Cascinu, Stefano
Di Lorenzo, Giuseppe
Cerbone, Linda
Ortega, Cinzia
Masini, Cristina
Giganti, Maria Olga
Lorusso, Vito
Messina, Caterina
Atzori, Francesco
De Vincenzo, Fabio
Sacco, Cosimo
Boccardo, Francesco
Valduga, Francesco
Massari, Francesco
Tassi, Renato
Procopio, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[3] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
Gruenwald, Viktor
Seidel, Christoph
Fenner, Martin
Woike, Michael
Kalanovic, Daniel
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[4] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
Elena, V.
Iacovelli, R.
Santoni, M.
Di Lorenzo, G.
Cerbone, L.
Ortega, C.
Masini, C.
Giganti, M. O.
Messina, C.
De Vincenzo, F.
Procopio, G.
BJU INTERNATIONAL, 2012, 110 : 5 - 5
[5] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
Iacovelli, R.
Santoni, M.
Di Lorenzo, G.
Cerbone, L.
Aglietta, M.
Masini, C.
Giganti, M. O.
Messina, C.
Sternberg, C. N.
Procopio, G.
ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
[6] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
Seidel, C.
Fenner, M.
Reuter, C. W.
Ganser, A.
Gruenwald, V.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[7] Progression-free survival (PFS) as a surrogate for overall survival (OS)
Stewart, David J.
Bosse, Dominick
Hilton, John
Goss, Glenwood
Fung-Kee-Fung, Michael
Jonker, Derek
CANCER RESEARCH, 2018, 78 (13)
[8] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
Halabi, Susan
Rini, Brian
Escudier, Bernard
Stadler, Walter M.
Small, Eric J.
CANCER, 2014, 120 (01) : 52 - 60
[9] Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
Motzer, R. J.
Escudier, B.
Bukowski, R.
Rini, B. I.
Hutson, T. E.
Barrios, C. H.
Lin, X.
Fly, K.
Matczak, E.
Gore, M. E.
BJU INTERNATIONAL, 2012, 109 : 8 - 8
[10] Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)
Motzer, R. J.
Escudier, B.
Bukowski, R.
Rini, B. I.
Hutson, T. E.
Barrios, C. H.
Lin, X.
Fly, K.
Matczak, E.
Gore, M. E.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S98 - S99

← 1 2 3 4 5 →